Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 8/20 | 0.36 |
| ▸ | CDK2 | P24941 | 8/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.36 |
| ▸ | SYK | P43405 | 3/20 | 0.36 |
| ▸ | MTOR | P42345 | 3/20 | 0.36 |
| ▸ | CDK4 | P11802 | 3/20 | 0.36 |
| ▸ | CCND3 | P30281 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879195 | 0.90 | SYK (0.38) | CCNA2CDK2SYKCDK4CSF1R | |
| SCHEMBL3879219 | 0.90 | SYK (0.40) | SYKCDK4CCND3 | |
| SCHEMBL1685269 | 0.87 | MAPKAPK5 (0.46) | CCNA2CDK2CCNA1SYKMTOR | |
| SCHEMBL1685210 | 0.87 | MAPKAPK5 (0.46) | CCNA2CDK2CCNA1SYKMTOR | |
| SCHEMBL1685148 | 0.81 | HRH3 (0.38) | CDK2SYKCDK4PIM1 | |
| SCHEMBL3868547 | 0.80 | MAPKAPK5 (0.34) | SYK | |
| SCHEMBL13922471 | 0.80 | MAPKAPK5 (0.47) | SYKMTORGSK3B | |
| SCHEMBL10165788 | 0.80 | CCNA2 (0.37) | CCNA2CDK2CCNA1SYKMTOR | |
| SCHEMBL1685139 | 0.77 | MAPKAPK5 (0.48) | SYKCDK4GSK3BPIM1CSF1R | |
| SCHEMBL10134531 | 0.76 | MAPKAPK5 (0.48) | CCNA2CDK2SYKCDK4CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | CCNA2 1641/4885CDK2 321/4885CCNA1 1258/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | CCNA2 1641/4885CDK2 321/4885CCNA1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.